Spying eye-watering profits at rival coronavirus vaccine developers, Vaxzevria manufacturer AstraZeneca (LSE: AZN) has taken a step towards boosting revenues with its first for-profits deal.
The announcement comes as the company reports revenue growth of 50% in the third quarter of 2021, at $9.9 billion, around $1 billion of which came from COVID vaccine sales.
The revenue result is a little higher than most analysts had been expecting. Following Generally Accepted Accounting Principles (GAAP), there was a loss per share in the third quarter of $1.10.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze